<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219242</url>
  </required_header>
  <id_info>
    <org_study_id>25543/16</org_study_id>
    <nct_id>NCT03219242</nct_id>
  </id_info>
  <brief_title>Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology</brief_title>
  <acronym>CAIMAN</acronym>
  <official_title>Longitudinal Prospective Study on Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Patients Using Caiman® Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal prospective study on primary debulking surgery including bowel resection in
      advanced stage ovarian cancer patients using Caiman® technology
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using CAIMAN® technology in primary surgery for advanced ovarian cancer including bowel
      resections.

      Analyze potential time-sparing and the incidence of post-surgical complications.

      Prospective, longitudinal, observational. 40 patients / year.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time-sparing for bowel resection</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Time needed for bowel resection and radical omentecomy in avanced ovarian cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post surgical complications</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>F-up in 1-3 and 6 months with questionnaire</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Caiman device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Caiman® device</intervention_name>
    <description>Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.</description>
    <arm_group_label>Caiman device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤ 75 years

          -  Patients with advanced ovarian cancer (FIGO stage IIIC-IV).

          -  Bowel resection

          -  Class 0-2 according to the American Society of Anesthesiologists (i.e.: ASA score ≤ 2)

          -  Written informed consent to the study

        Exclusion Criteria:

          -  Pregnant or chronic infections

          -  Previous pelvic radiotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Scambia, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Sacred Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart Rome,</name>
      <address>
        <city>Rome,</city>
        <state>Rome</state>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Scambia</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Advanced ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

